New Global Consortium to Advance First-Ever Clinical Testing of the Human Hookworm Vaccine in Sub-Saharan Africa

AMSTERDAM & WASHINGTON, DC – September 26, 2013 – The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world’s poorest people. Under this grant, the HOOKVAC consortium, which includes partners from the European Union, United States and Africa, will begin the first clinical testing of the human hookworm vaccine in the West African nation of Gabon.

On September 13th, the WHO South-East Asia Regional Committee announced a new commitment to eliminate measles and control rubella by 2020.

Sabin is happy to announce the arrival of our 2012 Annual Report, featuring highlights from our three programs – Vaccine Advocacy and Education, The

At Sabin’s Second Sustainable Immunization Financing Colloquium, held in Dakar, Senegal on 5-6 August, 2013, we had the chance to get a few thoughts from Zangad Bayanselenge, Member of the Great State of Hural and Chair of the Standing Committee on Social Policy, Education, Culture and Scien

Pages